Finished-dose partner supply

Losartan — Finished-Dose Partner Supply

Burrard Pharmaceuticals Enterprises Ltd., Vancouver, Canada, supports importers, distributors, and local marketing-authorisation holders seeking losartan finished-dose supply through a partner-site model.

Request losartan quality pack Contact page

Email bd@burrardpharma.com with your company, territory, and finished-dose supply, dossier support, or both.

Burrard does not manufacture in-house. Manufacture for this programme is placed with a qualified partner GMP site named under CDA.

Site GMP evidence is shared in the quality pack under CDA. Site GMP is not product approval.

This page discusses the INN losartan. Cozaar is named for identification only and is not a Burrard trademark or a Burrard-branded good.

Losartan is an angiotensin II receptor blocker in the established oral cardiovascular class.

Oral solid, strengths confirmed under CDA.

Losartan with hydrochlorothiazide, other combinations, other angiotensin receptor blockers, and salts not named on this page are out of scope unless separately confirmed under CDA.

Who this is for

Importers evaluating finished-dose supply for a named territory
Distributors whose registration or tender team needs documents before a commercial call
Local marketing-authorisation holders who will hold the destination authorisation themselves

Name losartan, not a brand combination, unless you intend to be told the combination is out of scope. Company, territory, and finished-dose supply, dossier support, or both are the items Burrard needs before a CDA.

How Burrard works on this programme

You name the territory. This page does not assume one.
CDA comes before the site name, batch certificates, or a dossier pack.
The partner GMP site is named under CDA.
The quality pack then holds the batch and site evidence that is actually available.
The local MAH or importer holds marketing authorisation. Burrard does not.

Programme attributes

Scope table. Public copy only. Strengths, packs, stability, and dossier status are confirmed under CDA, not on this page.

INN	Losartan
Dosage form	Oral solid, strengths confirmed under CDA
Strengths	Confirmed under CDA / quality pack
Pack sizes	Confirmed under CDA / quality pack
Stability / climate zone	Not stated. Confirmed under CDA.
Dossier format	Not asserted. Confirmed under CDA if a file is offered.
Facility class	Named site, in the quality pack.
WHO prequalification	Not claimed
Bioequivalence	Not claimed
MOQ / Incoterms	Confirmed under CDA
Exclusivity note	Long off-patent generic. US generic losartan has been marketed since 2010. The exact day and combination patents are not fixed here.

Finished-dose partner supply for importers and distributors

Burrard coordinates losartan finished-dose supply for commercial partners. Manufacture is at a qualified partner GMP site named under CDA, not at a Burrard plant. The reader is a partner, not a patient. This page is not a dose and not a superiority claim. Price and pack count are not published. The order of work is the quality pack, then site and batch evidence under CDA, then a short supply call.

What is in the quality pack?

A batch certificate of analysis, if one is available for the named configuration
GMP evidence for the named partner site
API documentation as applicable
Dossier-format availability only if confirmed, which is not a local approval
Pack, strength, and stability only for that named configuration

The pack is a B2B qualification file. It is not a marketing authorisation and not a patient leaflet.

Site GMP is not product approval

GMP or API documents describe the named site or the API. They are not Burrard product approval in the United States, the European Union, Canada, or elsewhere. This page claims no FDA, EMA, or Health Canada product approval and no country-of-origin marketing authorisation. The local MAH or importer holds the destination authorisation.

Exclusivity: long off-patent generic, US generic marketing since 2010

Losartan is a long off-patent generic. US generic losartan has been marketed since 2010. Published accounts differ on the exact calendar day once paediatric exclusivity is counted, so this page does not state a day. It also does not clear combination patents, including losartan with hydrochlorothiazide, and it does not say every country is open.

Burrard discusses supply only where relevant exclusivity has ended. Cozaar is an originator name for identification only, not a Burrard trademark.

Burrard does not quote a molecule under a live patent or exclusivity dispute in the requested territory. Supply is discussed only where relevant exclusivity has ended.

Related oral programmes

Each link is a separate finished-dose programme with its own exclusivity note. Valsartan.

Questions

Does Burrard manufacture losartan?

No. Burrard does not manufacture in-house. Manufacture is placed with a qualified partner GMP site named under CDA. The site is named in the quality pack after CDA.

Is Burrard's losartan FDA-approved, EMA-approved, or Health Canada-approved?

No. This page does not claim FDA, EMA, or Health Canada product approval for losartan. The local MAH or importer holds destination marketing authorisation. Site GMP evidence is not product approval.

What strengths and forms of losartan are stated publicly?

Oral solid, strengths confirmed under CDA. Pack size, stability zone, and CTD or ACTD status are not stated here.

Is the losartan with hydrochlorothiazide combination included?

No. This page is losartan, not the hydrochlorothiazide combination. Losartan is a long off-patent generic and US generic losartan has been marketed since 2010. That does not clear every combination or every country. Supply is discussed only where relevant exclusivity has ended.

How do I request losartan finished-dose supply?

Email bd@burrardpharma.com with your company, territory, and whether you need finished-dose supply, dossier support, or both. The quality pack and a short supply call follow CDA.

Request the quality pack

Email bd@burrardpharma.com with company, territory, and finished-dose supply, dossier support, or both. You can also use the contact page.

Request losartan quality pack Contact page

Disclaimer

For importers, distributors, and local marketing-authorisation holders only. Not patient information, not dosing guidance, and not an offer or a price. Burrard Pharmaceuticals Enterprises Ltd. does not manufacture in-house and does not claim FDA, EMA, or Health Canada product approval. Site GMP is not product approval. The local MAH or importer holds destination authorisation. Supply is discussed only where relevant exclusivity has ended. Strengths, packs, stability zones, and CTD status are confirmed under CDA, not here. Brand names are for identification only.